Bharath Advanced Therapeutics (BAT) and FABA Present Cancer NEXT 2024: Pioneering Innovation in Cancer Research
HYDERABAD, India, Nov. 29, 2024 /PRNewswire/ -- Bharath Advanced Therapeutics (BAT) and…
Launch of the 2025/2027 edition of the Advanced Olympic Research Grant Programme
26 November 2024 - The IOC Olympic Studies Centre (OSC) has launched a new edition…
Launch of the 2025/2027 edition of the Advanced Olympic Research Grant Programme
26 November 2024 - The IOC Olympic Studies Centre (OSC) has launched a new edition…
Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)
Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients…
Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)
Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients…
Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)
Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients…
Anocca Announces Submission of Clinical Trial Application for Multi-asset Trial VIDAR-1 in Advanced Pancreatic Cancer
November 26, 2024 03:00 ET | Source: Anocca AB Application to the…
Protecht launches advanced controls management solution
SYDNEY, Nov. 25, 2024 /PRNewswire/ -- Protecht Group, a global leader in…
Protecht launches advanced controls management solution
SYDNEY, Nov. 25, 2024 /PRNewswire/ -- Protecht Group, a global leader in…
IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer
FDA Project Team supports the company’s proposed Phase 3 trial strategy, including…